Carcinoid Heart Disease

Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.

Also Known As:

Networked: 148 relevant articles (8 outcomes, 8 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Carcinoid Tumor (Carcinoid)
2.	Heart Failure
3.	Amyloidosis
4.	Neoplasm Metastasis (Metastasis)
5.	Neuroendocrine Tumors (Neuroendocrine Tumor)

Experts

1.	Toumpanakis, Christos: 8 articles (09/2021 - 02/2008)
2.	Davar, Joseph: 7 articles (01/2018 - 02/2008)
3.	Bhattacharyya, Sanjeev: 6 articles (03/2017 - 02/2008)
4.	Connolly, Heidi M: 5 articles (01/2021 - 03/2003)
5.	Pavel, Marianne: 5 articles (01/2018 - 01/2010)
6.	Pellikka, Patricia A: 4 articles (01/2021 - 03/2003)
7.	Thiis-Evensen, Espen: 4 articles (03/2013 - 01/2009)
8.	Korse, Catharina M: 3 articles (05/2022 - 04/2003)
9.	Steeds, Richard P: 3 articles (03/2019 - 01/2016)
10.	Caplin, Martyn: 3 articles (01/2018 - 11/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Carcinoid Heart Disease:

1.	Biomarkers (Surrogate Marker)IBA 06/01/2021 - "The diagnosis of carcinoid heart disease is suspected by raised biomarkers, such as serum NT-pro-BNP and confirmed by imaging modalities, with echocardiogram being the gold standard to date. " 09/23/2021 - "In this review we discuss the use of established and novel biomarkers in the diagnosis and management of small intestine NETs and carcinoid heart disease." 09/23/2021 - "Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review." 01/01/2019 - "Carcinoid heart disease involving the left heart: a case report and biomarker analysis." 01/01/2013 - "The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study."
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/31/2018 - "The prognosis of patients with carcinoid heart disease has improved in recent years through somatostatin analogues and the cardiac surgery." 01/01/2018 - "These include new studies on its epidemiology which demonstrate it is increasing in frequency; increasing insights into the pathogenesis of its various clinical manifestations and into its natural history: definition of prognostic factors; new methods to verify its presence; the development of new drugs to treat its various manifestations, both initially and in somatostatin-refractory cases; and an increased understanding of the pathogenesis, natural history and management of carcinoid heart disease. " 06/01/2022 - "Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series." 01/01/2019 - "Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues." 10/01/2000 - "Medical therapy for carcinoid heart disease includes digitalis and diuretics for congestive heart failure symptoms; the effects of carcinoid syndrome can be treated with the use of somatostatin analogues. "
3.	pro-brain natriuretic peptide (1-76)IBA 09/10/2009 - "This study examined the diagnostic value of CgA and NT-proBNP for carcinoid heart disease (CHD), and their prognostic value for overall survival in NET patients. " 11/19/2019 - "Recent expert consensus guidelines highlight the role of echocardiography and screening with NT-proBNP for the evaluation of carcinoid heart disease. " 01/01/2013 - "NT-proBNP and plasma 5HIAA had the highest areas under the curve for the prediction of carcinoid heart disease [NT-proBNP 0.82 (95% confidence interval 0.74-0.90, p<0.0001) and 5HIAA 0.85 (95% confidence interval 0.78-0.92, p<0.0001]. " 05/10/2022 - "Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study." 01/01/2013 - "NT-proBNP and plasma 5HIAA are both sensitive and specific biomarkers for the presence of carcinoid heart disease whereas only NT-proBNP is moderately correlated with disease severity."
4.	Peptide Receptors (Peptide Receptor)IBA 06/01/2020 - "Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. " 09/01/2018 - "Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?" 01/01/2023 - "Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (177Lu) dotatate."
5.	Brain Natriuretic Peptide (Natrecor)FDA Link 10/01/2008 - "Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease." 10/01/2008 - "We sought to investigate whether N-terminal pro-brain natriuretic peptide (NT-pro-BNP) can be used as a biomarker for the detection of carcinoid heart disease (CHD); 200 patients with carcinoid syndrome were screened for CHD using transthoracic echocardiography. " 10/01/2023 - "The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease." 10/01/2023 - "N-terminal prohormone of brain natriuretic peptide (NT-proBNP) has previously been described as a useful biomarker in diagnosing carcinoid heart disease (CHD), a common advanced NETs manifestation. " 10/29/2021 - "Cardiac biomarkers proved also effective in patients with primary cardiac amyloidosis, in which both troponins and natriuretic peptides were able to predict adverse outcome, and carcinoid heart disease, where a precise diagnostic cut-off for N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was identified to screen patients with valvular involvement. "
6.	Natriuretic PeptidesIBA 06/01/2004 - "Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease." 10/29/2021 - "Cardiac biomarkers proved also effective in patients with primary cardiac amyloidosis, in which both troponins and natriuretic peptides were able to predict adverse outcome, and carcinoid heart disease, where a precise diagnostic cut-off for N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was identified to screen patients with valvular involvement. "
7.	Radioisotopes (Radionuclides)IBA 10/01/2018 - "Clinical Issues Related to Fluid Management during 177Lu-Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors with Carcinoid Heart Disease." 09/01/2018 - "Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?"
8.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 10/01/2020 - "The role of selective serotonin reuptake inhibitors in carcinoid heart disease is unclear. " 10/01/2020 - "Right and Left-Sided Carcinoid Heart Disease in the Setting of Selective Serotonin Reuptake Inhibitor Use." 10/01/2020 - "We present a case of refractory heart failure due to right- and left-sided carcinoid heart disease in the setting of selective serotonin reuptake inhibitor use despite remission of carcinoid syndrome. "
9.	TroponinIBA 10/29/2021 - "Cardiac biomarkers proved also effective in patients with primary cardiac amyloidosis, in which both troponins and natriuretic peptides were able to predict adverse outcome, and carcinoid heart disease, where a precise diagnostic cut-off for N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was identified to screen patients with valvular involvement. "
10.	lutetium Lu 177 dotatateIBA 09/01/2018 - "Considering the significantly shortened overall survival of patients with carcinoid heart disease, the relative paucity of available treatment options, and the risk of complications during corrective surgery on poorly controlled functioning disease, 177Lu-DOTATATE can emerge as a potent option in this group of patients." 09/01/2018 - "We report the gratifying response of functioning metastatic neuroendocrine tumor with carcinoid heart disease (uncontrolled by long-acting octreotide) to treatment with 177Lu-DOTATATE. " 09/01/2018 - "Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?"

Therapies and Procedures

1.	Therapeutics 03/01/2009 - "Cardiac surgery for symptomatic carcinoid heart disease in conjunction with adjunctive therapy is being increasingly shown to improve the long-term outlook of patients with carcinoid heart disease. " 11/24/2023 - "Development of targeted therapies against carcinoid heart diseases is currently limited by lack of understanding of pathophysiology of the disease processes. " 11/24/2023 - "Molecular biology of carcinoid heart disease: Seeking therapeutic targets in the era of targeted therapy." 11/19/2019 - "Advances in medical therapy along with better surgical outcomes highlight the experience and expertise that has been gained in the treatment of carcinoid heart disease. " 01/01/2018 - "Cardiac surgery, in appropriate cases, is the only definitive therapy for advanced carcinoid heart disease, and it improves patient symptoms and survival. "
2.	Surgical Instruments (Clip) 04/01/2020 - "Surgical valve replacement is the most effective treatment for carcinoid heart disease; however, reoperation for prosthetic valve failure is burdened by high risk. " 01/01/2018 - "Carcinoid Heart Disease: Early Outcomes after Surgical Valve Replacement in Nine Patients." 08/01/2016 - "This case report shows that percutaneous valve replacement can be a valid option in carcinoid heart disease patients who are not amenable to surgical valve replacement. " 04/15/2014 - "As haemodynamically significant carcinoid heart disease may be clinically silent, specific and individualised considerations must be made as to the most appropriate clinical criteria and time point at which surgical valve replacement should be undertaken in patients with carcinoid heart disease. " 06/01/2012 - "Carcinoid heart disease: outcomes after surgical valve replacement."
3.	Contraindications 09/01/2018 - "Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?"
4.	Bioprosthesis 04/01/2020 - "We report the first described percutaneous transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration for any reason in a patient with carcinoid heart disease. " 01/01/2016 - "Transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration in carcinoid heart disease." 11/01/1985 - "Two female patients with carcinoid heart disease, ages 56 and 32 years, underwent pulmonic valve resection surgery and tricuspid valve replacement with a porcine bioprosthesis. "
5.	Catheters 10/01/2018 - "Exercise cardiac magnetic resonance imaging with pulmonary artery catheter monitoring in carcinoid heart disease: a shift towards early intervention?" 01/01/2016 - "Staged Catheter-Based Valve Treatment of Severe Carcinoid Heart Disease."